STAT

•

Canal • 2 programas

Economía y empresa

Economía y empresa

Cada semana
Noticias

Noticias

Cada dos semanas

14 ENE

384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen

For this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco. The hosts are joined by ARCH Venture Partners co-founder and managing director Bob Nelsen and new Novo Nordisk CEO Mike Doustdar joins the podcast hosts live to discuss his first few months on the job and the company's push to regain market share in the competitive obesity market.

14 ene

•

1 h y 8 min
18/12/2025

382: Biotech's year in review

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.We also chat about Adam's picks for best and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk's direct-to-consumer offerings may be contributing to employers' decisions to drop coverage of weight loss drugs.

18/12/2025

•

34 min
29/05/2024

100: What happens when kids become caregivers?

When it comes to childhood and young adulthood, most people in the U.S. think of carefree times of life with few major responsibilities. But for a small subset of young people, these years also mean caring for loved ones. Harvard medical students Kimia Heydari and Romila Santra both have firsthand experience being young caregivers, and spoke with "First Opinion Podcast" host Pat Skerrett about the unique challenges of taking care of family members at ages when few of their peers had similar experiences.

29/05/2024

•

39 min
17/07/2025

361: Inside an FDA drug rejection, and layoffs at Sarepta

Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over manufacturing qualms? Ultragenyx CEO Emil Kakkis joins us to discuss what was in the rejection letter his company received late last week, and whether he still has confidence in FDA Commissioner Marty Makary. We also discuss Capricor’s drug rejection, and Sarepta’s decision to lay off hundreds of staffers, but give raises to some executives.

17/07/2025

•

43 min
18/12/2024

118: Dr. Glaucomflecken uses humor to spotlight the darkness in medicine

You’ve probably come across Will Flanary, aka Dr. Glaucomflecken, the internet’s most famous physician/comedian. For more than four years, the ophthalmologist has been gently roasting medicine by playing a rotating cast of characters — the emergency physician clad in cyclist gear, the “ortho bro,” the pediatrician in a unicorn headband. But he's also used his comedy to skewer the business of health care, including the confounding bureaucracies of insurance — with a special emphasis on UnitedHealthcare. First Opinion editor Torie Bosch spoke with Flanary about punching up in comedy and the reaction to the shooting of UnitedHealthcare CEO Brian Thompson.

18/12/2024

•

32 min
24/07/2025

362: A mother’s perspective on Sarepta’s gene therapy halt

We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration. We also talk about a rare mega-round for a new oncology biotech and an emerging class of drugs aimed at helping people stay awake.

24/07/2025

•

37 min
13/11/2024

114: Getting creative with health care in a new Trump administration

Torie speaks with Carmel Shachar, an assistant clinical professor at Harvard Law and health policy expert, about how the second Trump term might differ from the first, how the health policy world is preparing, and her work on reproductive health, telehealth, and vaccines.

13/11/2024

•

30 min
17/07/2024

107: Empathy should be the first response to people with vaccine injury, fears

For scientists and medical professionals well versed in the safety and effectiveness of vaccines, it is often too easy to write off the concerns of people who fear them, or feel they have been injured by them. But vaccine expert Kizzmekia S. Corbett-Helaire argues that professionals should be more empathetic when it comes to listening to these concerns, and that understanding them may help developers make better vaccines. Corbett-Helaire, an assistant professor of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health in Boston and a Freeman Hrabowski Scholar at the Howard Hughes Medical Institute, joins "The First Opinion Podcast" this week to discuss her experience helping roll out the first Covid-19 vaccines in the midst of the pandemic. She also addresses her desire to close the gap between public health experts trying to end disease and people who genuinely fear harm from vaccines.

17/07/2024

•

33 min
12/11/2025

James Watson’s lifelong friend and protégé on his complicated legacy

James Watson, who won the Nobel Prize for co-discovering the structure of DNA, died last week at the age of 97. He was a scientific giant, but in the final two decades of his life, he falsely stated that women and Black people are, as populations, not as smart as white men. Nancy Hopkins knew Watson better than most, having first worked with him when she was just an undergraduate. She is a retired MIT professor known for her work on zebrafish as a cancer model, and for her advocacy on behalf of women in science. Today, she is trying to reconcile her “lifelong friend,” the Watson one who encouraged her and other women to go into molecular biology, with the one who emerged late in life.

12/11/2025

•

37 min
20/11/2025

379: How Mark Cuban plans to ‘f— up’ health care

How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Cuban comes on for an extensive chat about the latest biosimilar launch by his company, Cost Plus Drugs, as well his broader thoughts on the drug industry and how the direct-to-consumer field is changing.We also chat about the news this week, including more M&A deals and an upcoming Alzheimer’s readout from Novo Nordisk.

20/11/2025

•

37 min

Voices from the frontiers of health and medicine